- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03317015
A Study to Assess Efficacy and Safety of Nasacort® Nasal Spray in Comparison With Flixonase® Nasal Spray in Adults Suffering From Perennial Allergic Rhinitis (PAR) (NASANIF)
April 22, 2022 updated by: Sanofi
A Randomized, Double-blind, Parallel-group, Multicenter, Phase III Prospective Non-inferiority Clinical Trial to Assess Efficacy and Safety of Nasacort® Nasal Spray (Triamcinolone, 55µg) in Comparison With Flixonase® Nasal Spray (Fluticasone, 50 µg) in Adults Suffering From PAR (Perennial Allergic Rhinitis) Administered Once a Day for 28 Days
Primary Objective:
- To assess efficacy of Nasacort® (triamcinolone) nasal spray, 55 µg per dose, in comparison with Flixonase® (fluticasone) nasal spray, 50 µg per dose, by reflective total nasal symptom score (rTNSS) (24 h) after 28 days of treatment compared with baseline (0 day of treatment) in adult patients suffering from PAR (perennial allergic rhinitis).
Secondary Objectives:
- To evaluate safety of Nasacort® (triamcinolone) nasal spray, in comparison with Flixonase® (fluticasone) administered for 28 days by assessment of adverse events reports.
- To evaluate patient and physician satisfaction after 28 days of treatment by 5-point scale.
- To estimate improvement of quality of life during the study by mini Rhinoconjunctivitis Quality of Life Questionnaire (miniRQLQ).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The total study duration per patient will be up to approximately 33 days.
Study Type
Interventional
Enrollment (Actual)
260
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion criteria:
- Females and males ≥18 and ≤50 years old.
- Patients with previously diagnosed PAR with a positive skin prick test response to an appropriate allergen performed not earlier than 12 months prior to the Screening visit.
- Patients must be clinically symptomatic (rTNSS reflecting symptoms for the previous 24 h ≥8 with two or more symptoms rated as moderate or severe).
- Negative urine pregnancy test during screening before first dose of study medication is administered in women with child-bearing potential.
- Women must use an effective contraceptive method during the study period.
- Patients should be able to understand the study, including risks and adverse events; collaborating with Investigator and proceed according with protocol.
- Signed informed consent form.
Exclusion criteria:
- Compromised ability to provide informed consent.
- Participation in any other clinical study.
- History of severe local reaction(s) or anaphylaxis to skin testing.
- Upper respiratory tract or sinus infection that required antibiotic therapy without at least a 14-day washout prior to the Screening Visit, or viral upper respiratory infection within 2 weeks prior to the Screening Visit.
- Subjects who have used any drug (Flixonase or Nasacort) in an investigational protocol 4 weeks prior to the Screening Visit.
- Female subjects who are breast-feeding, pregnant, or intend to become pregnant.
- Patients with nasal abnormalities, including nasal polyps, and marked septum deviation that interferes with nasal airflow.
- Recent (in the last 3 months) or unhealed nasal septum ulcers, nasal surgery, or nasal trauma.
- Specific immunotherapy finished later than 6 months prior to Visit 1.
Use of following medications:
- Intranasal corticosteroids within 4 weeks prior to Visit 1;
- Inhaled, oral, intramuscular, intravenous, ocular, and/or dermatological corticosteroid within 8 weeks prior to Visit 1;
- Cromones within 2 weeks prior to Visit 1;
- Short-acting antihistamines, including antihistamines contained in insomnia formulations within 3 days prior to Visit 1;
- Long-acting antihistamines within 10 days prior to Visit 1: loratadine, desloratadine, fexofenadine, cetirizine;
- Intranasal antihistamines within 2 weeks prior to Visit 1;
- Intranasal, oral, or inhaled anticholinergics within 3 days prior to Visit 1;
- Oral antileukotrienes within 3 days prior to Visit 1;
- Use of immunosuppressive medications 8 weeks prior to screening.
- Patients allergic to or have sensitivity to the study drug (triamcinolone acetonide, fluticasone propionate) or its excipients.
- Patients suffering from SAR (seasonal allergic rhinitis).
- Patients suffering from non-allergic rhinitis.
- Patients suffering from rhinitis medicamentosa.
- Patients suffering from non-allergic rhinitis caused by viral, bacterial etc infection.
- Patients suffering from bronchial asthma.
- Patients suffering from chronic sinusitis.
- In case of non-allergic rhinitis, nasal trauma or other condition that during the study can interfere with symptoms evaluation, subject would be excluded from the study.
- Patients with physical impairment that would affect subject's ability to participate safely and fully in the study.
- Clinical evidence of a Candida infection of the nose.
- History of psychiatric disease, intellectual deficiency, poor motivation, substance abuse (including drug and alcohol) or other conditions that will limit the validity of informed consent or that would affect the proper daily diary filling.
- Previous history and/or current diagnosis of glaucoma and cataract.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Group A - Nasacort®
Nasacort® will be sprayed twice in each nostril once every morning
|
Pharmaceutical form: spray solution Route of administration: nasal
Other Names:
|
ACTIVE_COMPARATOR: Group B - Flixonase®
Flixonase® will be sprayed twice in each nostril once every morning
|
Pharmaceutical form: spray solution Route of administration: nasal
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline in total nasal symptom score
Time Frame: From baseline (0 day of treatment) to 28th day of treatment
|
From baseline (0 day of treatment) to 28th day of treatment
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline in quality of life questionnaire scores (miniRQLQ questionnaire)
Time Frame: From baseline (0 day of treatment) to 28th day of treatment
|
From baseline (0 day of treatment) to 28th day of treatment
|
Number of participants with adverse events
Time Frame: From baseline (0 day of treatment) to 28th day of treatment
|
From baseline (0 day of treatment) to 28th day of treatment
|
Assessment of patient satisfaction using the 5-point scale questionnaire
Time Frame: 28th day of treatment
|
28th day of treatment
|
Assessment of physician satisfaction using the 5-point scale questionnaire
Time Frame: 28th day of treatment
|
28th day of treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
November 30, 2016
Primary Completion (ACTUAL)
July 10, 2017
Study Completion (ACTUAL)
July 10, 2017
Study Registration Dates
First Submitted
October 18, 2017
First Submitted That Met QC Criteria
October 18, 2017
First Posted (ACTUAL)
October 23, 2017
Study Record Updates
Last Update Posted (ACTUAL)
April 25, 2022
Last Update Submitted That Met QC Criteria
April 22, 2022
Last Verified
April 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Immune System Diseases
- Hypersensitivity, Immediate
- Otorhinolaryngologic Diseases
- Respiratory Hypersensitivity
- Hypersensitivity
- Nose Diseases
- Rhinitis
- Rhinitis, Allergic
- Rhinitis, Allergic, Perennial
- Physiological Effects of Drugs
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Dermatologic Agents
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Anti-Allergic Agents
- Triamcinolone
- Fluticasone
Other Study ID Numbers
- TRICAL07830
- U1111-1178-4882 (OTHER: UTN)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications.
Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants.
Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rhinitis Allergic
-
Universitaire Ziekenhuizen KU LeuvenAZ Sint-Jan AVRecruitingPerennial Allergic Rhinitis | Seasonal Allergic Rhinitis | Local Allergic RhinitisBelgium
-
Organon and CoCompletedPerennial Allergic Rhinitis | Seasonal Allergic Rhinitis
-
Humanis Saglık Anonim SirketiCompletedPerennial Allergic Rhinitis | Seasonal Allergic RhinitisIndia
-
Organon and CoCompletedPerennial Allergic Rhinitis | Seasonal Allergic Rhinitis
-
Organon and CoCompletedPerennial Allergic Rhinitis | Seasonal Allergic Rhinitis
-
ALK-Abelló A/SCompletedPerennial Allergic Rhinitis | Seasonal Allergic Rhinitis
-
West Penn Allegheny Health SystemPennsylvania Allergy and Asthma Research FoundationCompletedAllergy | Perennial Allergic Rhinitis | Seasonal Allergic RhinitisUnited States
-
Ahn-Gook Pharmaceuticals Co.,LtdSamsung Medical Center; Seoul St. Mary's Hospital; Seoul National University... and other collaboratorsCompletedAllergic Rhinitis | Perennial Allergic Rhinitis | Non-seasonal Allergic RhinitisKorea, Republic of
-
Eli Lilly and CompanyNot yet recruitingPerennial Allergic Rhinitis (PAR)United States
-
Glenmark Specialty S.A.CompletedSeasonal Allergic Rhinitis (SAR)United States
Clinical Trials on triamcinolone XRG5029
-
Peking University Third HospitalActive, not recruitingOsteoarthritis, KneeChina
-
Hospital de BragaUniversity of MinhoUnknown
-
Jaeb Center for Health ResearchNational Eye Institute (NEI)CompletedDiabetic Macular Edema
-
University of California, San FranciscoGenentech, Inc.Terminated
-
Montefiore Medical CenterTerminatedHidradenitis SuppurativaUnited States
-
Wuhan UniversityRecruitingRefractory Granulomatous Lobular MastitisChina
-
Shin Kong Wu Ho-Su Memorial HospitalNational Science Council, TaiwanCompletedSubacromial Impingement Syndrome | Rehabilitation | Physical Therapy | Subacromial Bursitis | Therapeutic ExerciseTaiwan
-
Weill Medical College of Cornell UniversityCompletedNail Diseases | Nail PsoriasisUnited States
-
Clearside Biomedical, Inc.CompletedPanuveitis | Uveitis | Posterior Uveitis | Intermediate Uveitis | Noninfectious UveitisUnited States
-
SurModics, Inc.CompletedDiabetic Macular EdemaUnited States